Multivalent Swine Vaccine Merging Antigens to Reduce Efficacy Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Mycoplasma hyopneumoniae, Porcine Circovirus type 2, and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in swine are inefficient due to 'efficacy interference' when co-administered, requiring multiple doses and increasing costs and logistical challenges in vaccination.
Innovation Solution
A polyvalent vaccine composition comprising an M. hyo antigen combined with either a PCV2 antigen or a PRRSV antigen, including a modified-live and inactivated PRRSV antigen, to induce a protective immunogenic response in animals, reducing death loss and improving weight gain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple separate vaccines are administered to cover M. hyo, PCV2, and PRRSV infections, then comprehensive protection against multiple pathogens is achieved, but efficacy interference occurs and multiple dosing is required
Solution Approach 1:
The patent combines multiple vaccine components (M. hyo, PCV2, and PRRSV antigens) into a single multivalent vaccine formulation. This merging approach allows simultaneous administration of multiple vaccines, eliminating efficacy interference that occurs when separate vaccines are co-administered, while maintaining comprehensive protection against all three pathogens.
Solution Approach 2:
The multivalent vaccine serves multiple functions by providing protection against three different pathogens (M. hyo, PCV2, and PRRSV) through a single administration. This multi-functionality eliminates the need for separate vaccine administrations, reducing overall dosing requirements while maintaining broad protective coverage.
2Reliability
If multiple separate vaccinations are administered, then comprehensive pathogen coverage is achieved, but vaccination costs and logistical complexity increase
Solution Approach 1:
By merging three separate vaccine preparations into one multivalent formulation, the patent simplifies vaccination logistics. Veterinarians and farmers need to administer only one vaccine instead of three separate vaccines, reducing the complexity of vaccination programs while maintaining coverage against all targeted pathogens.
Solution Approach 2:
The single multivalent vaccine provides universal coverage against multiple pathogens, eliminating the need for multiple separate vaccination administrations. This reduces logistical complexity in terms of tracking multiple dosing schedules, storage requirements, and administration procedures while maintaining comprehensive pathogen coverage.
3Reliability
If separate vaccines are used for M. hyo and PRRSV, then specific immunity to each pathogen is achieved, but the number of doses required increases
Solution Approach 1:
The patent merges M. hyo and PRRSV vaccine components into a single multivalent formulation that can be administered in one dose. This maintains specific immunity to both pathogens while reducing the total number of doses required from multiple separate administrations to a single combined administration.
Solution Approach 2:
The multivalent vaccine provides universal protection against multiple pathogens through a single dose, eliminating the need for multiple separate dosing events. This reduces time loss associated with multiple vaccination visits or administrations while maintaining the specific immunity required for each pathogen.
Data Source
AI summary
The present invention relates to compositions or vaccines for combating Mycoplasma hyopneumoniae (M hyo), Porcine Circovirus type 2 (PCV2), and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infections in animals and for increasing the ability of pigs to gain weight and/or improve death loss, methods of vaccination against the infections, and kits for use with such methods and compositions.